睿知中国疾病研究地图
候选清单0

正在招募肝细胞癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Phase I Study of OriC902 in Treatment of Advanced HCC

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验,由北京大学肿瘤医院牵头,本站收录的另外 1 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 2

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)北京大学肿瘤医院Peking University Cancer Hospital北京医院页面
  2. 研究中心北京高博医院Beijing GoBroad Hospital北京医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06891742,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Child-Pugh A or B7 without hepatic encephalopathy;

    入选标准第 7 条

  3. According to RECIST 1.1, subjects have at least one measurable lesion (lesions that have received local treatment such as radiotherapy need to be identified by imaging for definite progression), and the longest diameter at baseline for CT or MRI imaging evaluation must be ≥10 mm (except lymph nodes, whose short diameter must be ≥15 mm);

    入选标准第 10 条

    Fertile men and women of childbearing age must consent to the use of effective contraception from the signing of the master informed consent until 2 years after the study drug use. Women of reproductive age include women before menopause and women within 2 years after menopause. Blood pregnancy tests for women of childbearing age must be negative at the time of screening.

    入选标准第 13 条

    Previously received anti-tumor therapy against GPC3 targets, including but not limited to antibodies, ADCs (antibody-coupled drugs) and cell therapy;

    排除标准第 7 条

    Major surgical treatment (other than liver space biopsy) was performed within 28 days prior to apheresis, or major surgical treatment was planned during the study period;

    排除标准第 10 条

  4. An ECOG score of 0 or 1;

    入选标准第 8 条

  5. Hepatitis B surface antigen (HBsAg) positive or Hepatitis B core antibody (HBcAb) positive, and HBV-DNA > 500 IU/mL. (For HBsAg positive or HBCAB-positive patients, antiviral therapy should be performed for at least 4 weeks before the first administration of the study drug, and antiviral therapy should be continued during the study);

    排除标准第 4 条

    Hepatitis C virus (HCV) antibody positive and peripheral blood HCV RNA positive; Human immunodeficiency virus (HIV) antibody positive; Syphilis specific antibody positive and syphilis non-specific antibody positive; Cytomegalovirus (CMV) DNA test positive, EBV-DNA test positive;

    排除标准第 5 条

    Investigators assessed that the intrahepatic tumor occupied more than 50% of the entire liver; The presence of main portal vein cancer thrombus or inferior vena cava cancer thrombus;

    排除标准第 8 条

  6. Pregnant or lactating female subjects;

    排除标准第 23 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06891742,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Understand and voluntarily sign an informed consent form (ICF) prior to conducting any assessment/procedure related to the study;
  2. Ages 18 to 75 at the time of signing the ICF (including 18 and 75);
  3. HCC was diagnosed according to the Primary Liver Cancer Diagnosis and Treatment Guidelines (2024 edition);
  4. Samples of liver tumor tissue or extrahepatic metastases within 1 year of signing the pre-screening informed consent were 1+ or more positive by immunohistochemical detection of GPC3 in tumor cells of at least 5% (dose escalation phase) or 10% (dose expansion phase);
  5. BCLC stage B HCC or BCLC stage C HCC that are not suitable for local therapy or relapse after local therapy and cannot be cured;
  6. Failure of standard treatment (including but not limited to targeted therapy, immunotherapy, or chemotherapy), which is determined by imaging as disease progression;
  7. Child-Pugh A or B7 without hepatic encephalopathy;
  8. An ECOG score of 0 or 1;
  9. The expected survival is not less than 12 weeks;
  10. According to RECIST 1.1, subjects have at least one measurable lesion (lesions that have received local treatment such as radiotherapy need to be identified by imaging for definite progression), and the longest diameter at baseline for CT or MRI imaging evaluation must be ≥10 mm (except lymph nodes, whose short diameter must be ≥15 mm);
  11. Can carry out normal venous blood collection and machine simple collection, can establish the necessary venous access for collection, no contraindications for white blood cell collection;
  12. The researchers judged that lymphocyte clearance therapy could be performed;
  13. Fertile men and women of childbearing age must consent to the use of effective contraception from the signing of the master informed consent until 2 years after the study drug use. Women of reproductive age include women before menopause and women within 2 years after menopause. Blood pregnancy tests for women of childbearing age must be negative at the time of screening.

排除标准:Exclusion Criteria:

  1. Central nervous system (CNS) metastasis, meningeal metastasis, or spinal cord compression;#
  2. Have a history of allogeneic hematopoietic stem cell transplantation or organ transplantation;
  3. A history of other primary malignancies within 3 years prior to study treatment, except for the following: Adequate treatment of cured carcinoma in situ (including but not limited to cervical carcinoma in situ, breast carcinoma in situ, etc.); Adequate treatment of cured localized basal cell or squamous cell carcinoma of the skin;
  4. Hepatitis B surface antigen (HBsAg) positive or Hepatitis B core antibody (HBcAb) positive, and HBV-DNA > 500 IU/mL. (For HBsAg positive or HBCAB-positive patients, antiviral therapy should be performed for at least 4 weeks before the first administration of the study drug, and antiviral therapy should be continued during the study);
  5. Hepatitis C virus (HCV) antibody positive and peripheral blood HCV RNA positive; Human immunodeficiency virus (HIV) antibody positive; Syphilis specific antibody positive and syphilis non-specific antibody positive; Cytomegalovirus (CMV) DNA test positive, EBV-DNA test positive;
  6. People who are allergic to any of the drug components to be used in this study, including but not limited to antisepsis drugs (albumin paclitaxel, cyclophosphamide, fludarabine);
  7. Previously received anti-tumor therapy against GPC3 targets, including but not limited to antibodies, ADCs (antibody-coupled drugs) and cell therapy;
  8. Investigators assessed that the intrahepatic tumor occupied more than 50% of the entire liver; The presence of main portal vein cancer thrombus or inferior vena cava cancer thrombus;
  9. Patients who received the following anti-tumor therapy before anapheresis: Received cytotoxic chemotherapeutic drugs within 28 days (combination chemotherapy) or 14 days (single agent chemotherapy) or 5 half-lives (whichever time the investigator determines is more appropriate); received any investigational drug/treatment within 28 days; received antibody drugs within 21 days; received a small molecule targeted drug within 14 days or 5 halflives (whichever is more appropriate in the investigator's judgment); received local treatment and/or radiotherapy within 28 days; received Chinese medicine with anti-tumor indications within 7 days;
  10. Major surgical treatment (other than liver space biopsy) was performed within 28 days prior to apheresis, or major surgical treatment was planned during the study period;
  11. Toxicity from previous antitumor therapy has not returned to grade 1 or baseline levels (according to NCI-CTCAE version 5.0), except in the following cases: alopecia, depigmentation, or partial chronic stable state grade 2 AE (such as hypothyroidism controlled by alternative therapy) and other toxicity determined by the investigator to be of no safety risk;
  12. Any uncontrolled active infection during the 4 weeks prior to apheresis that requires antibiotic, antiviral, or antifungal treatment;
  13. A history of active pulmonary tuberculosis infection within 1 year prior to anapheresis (except for subjects with a history of active pulmonary tuberculosis infection more than 1 year ago if the investigator determines that there is no evidence of active pulmonary tuberculosis at present);
  14. accompanied or prior history of interstitial lung disease or interstitial pneumonia; Patients with extensive lung metastasis or other severe lung disease whose lung function has been assessed by the investigator to be unable to tolerate treatment with the investigational drug;
  15. Have an active or past autoimmune disease that may recur (e.g., systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vasculitis and psoriasis);
  16. Patients who required systemic corticosteroids (doses equal to or greater than 10 mg/ day) or other immunosuppressive drugs within 2 weeks of preapheresis or during the study period, except in the following cases: Intranasal, inhaled, local steroid or local steroid injection (Such as intra-articular injection), or systemic corticosteroid therapy not exceeding 10 mg/ day of prednisone or its physiological equivalent;
  17. Cardiovascular diseases of clinical significance#
  18. Insufficient bone marrow functional reserve or organ function#
  19. Bleeding events that have obvious clinical significance and require medical intervention occurred within 28 days prior to anapheresis; There was a significantly increased risk of gastrointestinal bleeding during the study period as assessed by the investigators;
  20. Patients with poorly controlled pleural effusion, pericardial effusion or abdominal and pelvic effusion who were judged unsuitable for inclusion by the investigator;
  21. Had received live attenuated vaccine within 28 days prior to anapheresis, or planned to receive live attenuated vaccine during the study period#
  22. Patients with a history of mental disorders or substance abuse were unable to participate in the study#
  23. Pregnant or lactating female subjects;
  24. The investigator considers that other conditions of the subjects may affect their adherence to the protocol or are not suitable for participation in the study.

引自 ClinicalTrials.gov, NCT06891742, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06891742,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06891742